Last reviewed · How we verify

NCT04667442

Investigational Performance Evaluation of the Nanomix eLab® COVID-19 Rapid Antigen Panel With Samples From COVID-19 Positive and Negative Human Subjects

Completed Last updated 27 December 2021
What this trial tests

trial testing Nanomix eLab® COVID-19 Rapid Antigen Panel (non-interventional) in Covid19 in 137 participants. Completed in 14 December 2021.

Timeline
1 December 2020
Primary endpoint
14 December 2021
14 December 2021

Quick facts

Lead sponsorNanomix
StatusCompleted
Study typeOBSERVATIONAL
Enrollment137
Start date1 December 2020
Primary completion14 December 2021
Estimated completion14 December 2021
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Nanomix

Who can join

18 and older, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective samples will be collected to evaluate the agreement between a EUA RT-PCR test as the comparator method against the Nanomix eLab® system.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Covid19

Currently open trials in the same condition.

Other Nanomix trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04667442.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing